

Part 1. HBV Replication Cycle References

1. World Health Organization. Global Hepatitis Report 2026. Geneva: WHO; 2026. <https://www.who.int/publications/i/item/9789240122383>
2. Polaris Observatory Collaborators. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study. *Lancet Gastroenterol Hepatol*. 2023;8(10):879-907.
3. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatitis B virus infection. *J Hepatol*. 2025;84(5). [https://www.journal-of-hepatology.eu/article/S0168-8278\(25\)00174-6/fulltext](https://www.journal-of-hepatology.eu/article/S0168-8278(25)00174-6/fulltext)
4. Yan H, Zhong G, Xu G, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. *eLife*. 2012;1:e00049.
5. Ni Y, Lempp FA, Mehrle S, et al. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. *Gastroenterology*. 2014;146(4):1070-1083.
6. Seeger C, Mason WS. Molecular biology of hepatitis B virus infection. *Virology*. 2015;479-480:672-686.
7. Nassal M. HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B. *Gut*. 2015;64(12):1972-1984.
8. Zoulim F, Chen PJ, Dandri M, Kennedy PT, Seeger C. Hepatitis B virus DNA integration: implications for diagnostics, therapy, and outcome. *J Hepatol*. 2024;81(6):1087-1099.
9. Zoulim F, Durantel D. Antiviral therapies and prospects for a cure of chronic hepatitis B. *Cold Spring Harb Perspect Med*. 2015;5(4):a021501.